Impact on urinary oxalate levels with use of ezetimibe
Abstract Background Calcium oxalate stones are the most common cause of nephrolithiasis in the United States. Smaller studies of <15 patients investigating ezetimibe, a selective cholesterol absorption inhibitor, have suggested increased urine oxalate levels with use of the drug. We attempt to be...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-04-01
|
Series: | Endocrinology, Diabetes & Metabolism |
Online Access: | https://doi.org/10.1002/edm2.221 |